Clinical trials: Cardiomegaly
Artificial Intelligence, Lung Diseases
Retrospective Study of Carebot AI CXR Performance in Preclinical Practice
The purpose of this study is to describe the design, methodology and evaluation of the preclinical test of Carebot AI CXR software, and to provide evidence that the investigated medical device meets user requirements in…
- Conditions
- Artificial Intelligence, Lung Diseases, Pneumothorax, Pleural Effusion
- Trial name
- NCT05594485
- Testing
- Carebot AI CXR
- Where
- Czechia
- Volunteers
- 127 people
- Sponsor
- Carebot s.r.o.
Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy
A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure
The purpose of this trial is to assess whether MYDICAR can reduce the frequency and/or delay heart failure related hospitalizations in persons with advanced heart failure when added to their maximal and optimized therapy.
- Conditions
- Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure, Cardiomyopathies
- Trial name
- CUPID-2b (NCT01643330)
- Testing
- AAV1/SERCA2a (MYDICAR)
- Where
- 54 sites in United States, Belgium and 8 more
- Volunteers
- 250 people
- Sponsor
- Celladon Corporation
Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy
A Phase 1/2 Study of High-dose Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure
The purpose of this trial is to characterize the safety profile and preliminary activity of high-dose MYDICAR® in persons with advanced heart failure when added to their maximal and optimized therapy.
- Conditions
- Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy, Heart Failure, Cardiomyopathies
- Trial name
- NCT02346422
- Testing
- MYDICAR Phase 1, MYDICAR Phase 2
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Celladon Corporation
Primary Familial Dilated Cardiomyopathy
Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities
The purpose of this Phase 2a study is to establish safety and preliminary efficacy of treatment with danicamtiv in patients with primary dilated cardiomyopathy (DCM) due to MYH7 or TTN variants or other causalities.
- Trial name
- NCT04572893
- Testing
- danicamtiv
- Where
- 19 sites in United States, Germany and 2 more
- Volunteers
- 41 people
- Sponsor
- Bristol-Myers Squibb
Dilated Cardiomyopathy
ACC - Atrial Contribution to CRT
This prospective study will evaluate in patients, fulfilling implant criteria for Cardiac Resynchronisation Therapy (CRT) implant, the optimal atrial contribution to the resynchronised ventricles in the event of right atrial…
- Trial name
- NCT00180323
- Testing
- Renewal
- Where
- Denmark
- Volunteers
- 43 people
- Sponsor
- Boston Scientific Corporation
Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction…
- Trial name
- NCT04331769
- Testing
- AccuCinch Ventricular Restoration System, Guideline-Directed Medical Therapy
- Where
- 122 sites in United States, Belarus and 8 more
- Volunteers
- 400 people
- Sponsor
- Ancora Heart, Inc.
Hypertension and Left Ventricular Hypertrophy (Thickening of the Main Pumping Chamber of the Heart)
Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study (0954-133)
The LIFE study was conducted from 1995-2001. This study was conducted in 9193 patients with high blood pressure and thickening of the main pumping chamber of the heart.
- Trial name
- NCT00338260
- Testing
- MK0954, /Duration of Treatment : 5 Years, Comparator : atenolol /Duration of Treatment : 5 Years
- Volunteers
- 496 people
- Sponsor
- Organon and Co